Roche declines SYN120 option

Biotie Therapies Corp. (HSE:BTH1V) said Roche (SIX:ROG; OTCQX:RHHBY) declined to exercise its option to regain rights to cognitive impairment product SYN120, citing "strategic portfolio reasons." The oral serotonin (5-HT6) receptor antagonist completed Phase I testing. According to Biotie, a number of companies have expressed interest in the compound and Biotie said it is confident it will find a partner. Details were not disclosed. ...